OBJECTIVE: To determine whether inhaled NO (iNO) can reduce pulmonary vascular resistance in adults with congenital heart disease and obstructive pulmonary hypertension or Eisenmenger syndrome. DESIGN: 23 patients received graded doses of iNO. Pulmonary and systemic haemodynamic variables and circulating cyclic guanosine monophosphate (cGMP) concentrations were measured at baseline and after 20 and 80 ppm iNO. Patients were considered responders when total pulmonary resistance was reduced by at least 20%, and rebound was defined as a greater than 10% increase in total pulmonary resistance upon withdrawal from iNO. RESULTS: In response to 20 ppm iNO, total pulmonary resistance decreased in four patients (18%, 95% confidence interval (CI), 2% to 34%), while in response to 80 ppm iNO it decreased in six patients (29%, 95% CI 10% to 38%). Systemic blood pressure did not change. Withdrawal resulted in rebound in three patients (16%, 95% CI 0% to 32%) after cessation of 20 ppm iNO, and in six patients (35%, 95% CI 12% to 58%) after cessation of 80 ppm iNO. Patients with predominant right to left shunting did not respond. In all patients cGMP increased from (mean (SD)) 28 (13) micromol/l at baseline to 55 (30) and 78 (44) micromol/l after 20 and 80 ppm iNO (p < 0.05 v baseline). CONCLUSIONS: NO inhalation is safe and is associated with a dose dependent increase in circulating cGMP concentrations. Pulmonary vasodilatation in response to iNO was observed in 29% of patients and was influenced by baseline pulmonary haemodynamics. Responsiveness to acute iNO may identify patients with advanced obstructive pulmonary hypertension and Eisenmenger syndrome who could benefit from sustained vasodilator treatment.
OBJECTIVE: To determine whether inhaled NO (iNO) can reduce pulmonary vascular resistance in adults with congenital heart disease and obstructive pulmonary hypertension or Eisenmenger syndrome. DESIGN: 23 patients received graded doses of iNO. Pulmonary and systemic haemodynamic variables and circulating cyclic guanosine monophosphate (cGMP) concentrations were measured at baseline and after 20 and 80 ppm iNO. Patients were considered responders when total pulmonary resistance was reduced by at least 20%, and rebound was defined as a greater than 10% increase in total pulmonary resistance upon withdrawal from iNO. RESULTS: In response to 20 ppm iNO, total pulmonary resistance decreased in four patients (18%, 95% confidence interval (CI), 2% to 34%), while in response to 80 ppm iNO it decreased in six patients (29%, 95% CI 10% to 38%). Systemic blood pressure did not change. Withdrawal resulted in rebound in three patients (16%, 95% CI 0% to 32%) after cessation of 20 ppm iNO, and in six patients (35%, 95% CI 12% to 58%) after cessation of 80 ppm iNO. Patients with predominant right to left shunting did not respond. In all patientscGMP increased from (mean (SD)) 28 (13) micromol/l at baseline to 55 (30) and 78 (44) micromol/l after 20 and 80 ppm iNO (p < 0.05 v baseline). CONCLUSIONS: NO inhalation is safe and is associated with a dose dependent increase in circulating cGMP concentrations. Pulmonary vasodilatation in response to iNO was observed in 29% of patients and was influenced by baseline pulmonary haemodynamics. Responsiveness to acute iNO may identify patients with advanced obstructive pulmonary hypertension and Eisenmenger syndrome who could benefit from sustained vasodilator treatment.
Authors: O Sitbon; M Humbert; J L Jagot; O Taravella; M Fartoukh; F Parent; P Herve; G Simonneau Journal: Eur Respir J Date: 1998-08 Impact factor: 16.671
Authors: Saurabh Aggarwal; Christine M Gross; Sanjiv Kumar; Sanjeev Datar; Peter Oishi; Gokhan Kalkan; Christian Schreiber; Sohrab Fratz; Jeffrey R Fineman; Stephen M Black Journal: J Cell Physiol Date: 2011-12 Impact factor: 6.384
Authors: Maria Jesus Del Cerro; Shahin Moledina; Sheila G Haworth; Dunbar Ivy; Maha Al Dabbagh; Hanaa Banjar; Gabriel Diaz; Alexandria Heath-Freudenthal; Ahmed Nasser Galal; Tilman Humpl; Snehal Kulkarni; Antonio Lopes; Ana Olga Mocumbi; G D Puri; Beyra Rossouw; S Harikrishnan; Anita Saxena; Patience Udo; Lina Caicedo; Omar Tamimi; Ian Adatia Journal: Pulm Circ Date: 2016-03 Impact factor: 3.017
Authors: Harald Kaemmerer; Siegrun Mebus; Ingram Schulze-Neick; Andreas Eicken; Pedro T Trindade; Alfred Hager; Erwin Oechslin; Koichiro Niwa; Irene Lang; John Hess Journal: Curr Cardiol Rev Date: 2010-11
Authors: Jue Seong Lee; Seul Gi Cha; Gi Beom Kim; Sang Yun Lee; Mi Kyoung Song; Hye Won Kwon; Eun Jung Bae; Jae Gun Kwak; Woong Han Kim; Jeong Ryul Lee Journal: J Cardiovasc Imaging Date: 2019-10